PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10247655

Compounding and repackaging--a need for complete records.

R A Proksch
View original source ↗Export metadata ↓

Abstract

The necessity for adequate record systems is discussed in relation to repackaging and compounding activities. Sample forms are presented. Basic requirements associated with governmental and professional regulations and guidelines are detailed. Specific governmental regulatory agencies do not now directly monitor hospital pharmacy in terms of Good Manufacturing Practices; however, professional and legal criteria should be appraised to account for what may be construed as the "state of the art." An example of one type of record system is presented for review.

Explore related subjects

Drug CompoundingDrug PackagingHospital Bed Capacity, 500 and overHospital RecordsMarylandPharmacy Service, HospitalRecordsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R A Proksch. 1980. Compounding and repackaging--a need for complete records.. https://pubmed.ncbi.nlm.nih.gov/10247655/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

A correction factor for bridging compaction simulator and different roller compactors.

Roller compaction (RC) is an important dry granulation technique. Since pilot and commercial scale roller compactors, which operate continuously on a large scale, usually require kilograms of material per run, formulation and process development directly on such roller compactors is not practical. In contrast, a compaction simulator (CS) can produce ribblets, also known as "slugs", using only a few grams of material with sinusoidal displacement profile replicating the motion of a specific point on the roll surface. Thus, it is possible to develop RC formulation and process in laboratory using a CS-based material-sparing approach. However, because of the inherently different configurations for applying pressure between die compression and roll compression, translating uniaxial pressure from CS experiments to roll pressure during RC is often unreliable, leading to significant uncertainties in the critical quality attributes of ribbons, such as ribbon solid fraction (or porosity) and mechanical strength. The objective of this study was to identify a correction factor (Kp = uniaxial die compression pressure/roll pressure), by correlating the compressibility profiles from CS and a roller compactor of interest, to enable more reliable process translation from CS to roller compactor. In this study, a Kp value of 0.5 was determined for Alexanderwerk WP120 and validated for Gerteis Mini-Pactor and Bepex Pharmapactor. This value may serve as a starting point for translating the optimal compaction pressure identified based on CS investigation to common roller compactors, requiring only minor adjustments to attain optimal RC process parameters (i.e., roll force and roll gap) for a chosen roller compactor.

Drug Compounding↗
PubMed2002

Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy.

153Sm, an attractive therapeutic radionuclide, was produced by neutron activation of both natural Sm2O3 and 98% enriched 152Sm2O3 targets. The production logistics and radionuclidic purity aspects of 153Sm obtained using both these targets are discussed with respect to the intended end use for metastatic bone pain palliation (MBPP) in terminal cancer patients and radiation synovectomy (RS) of medium size joints. The specific activity of 153Sm obtained was around 11 GBq x mg(-1) (approximately 300 mCi x mg(-1)) and 44 GBq x mg(-1) (approx. 1200 mCi x mg(-1)) from natural and enriched targets, respectively. The level of the long-lived radionuclidic impurity burden in 153Sm obtained from the natural Sm2O3 targets, namely, due to 154Eu (5 Bq x MBq(-1) 153Sm (5 nCi x mCi(-1) 153Sm)) and 155Eu (75 Bq x MBq(-1) 153Sm (75 nCi x mCi(-1) 153Sm)), appears low enough not to pose a problem, both in the palliative treatment of terminal cancer patients (at 1.85-2.22 GBq (50-60 mCi) dose) as well as in RS (at 74 MBq (2 mCi) dose). The 154Eu content in 153Sm from the enriched target was comparable, while, as expected, the level of 155Eu was nearly two orders of magnitude lower. There is a notable overall advantage of 153Sm over the use of 186Re, the other radionuclide of interest for the same purposes.

Drug Compounding↗
PubMed2001

Evaluation of model solvent systems for assessing the accumulation of container extractables in drug formulations.

The interaction between a medical device and a pharmaceutical solution it contacts may dictate solution safety and/or efficacy. Of specific concern is the ability of device components to leach into the contacting solution. As pharmaceutical solutions containing surfactants, co-solvents and solubilizing agents become more common, method's for assessing the extent of leaching are needed. In this manuscript, a model is developed which relates a solution's polarity to its ability to interact with a plastic material. The validity of the developed model is examined via direct analysis of several pharmaceutically relevant solutions.

Drug Compounding↗